DDD Partners LLC Boosts Stock Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

DDD Partners LLC boosted its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 165.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 601,050 shares of the company's stock after buying an additional 374,976 shares during the quarter. DDD Partners LLC owned approximately 0.09% of Genmab A/S worth $11,769,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Deep Track Capital LP purchased a new position in Genmab A/S in the 4th quarter worth approximately $41,740,000. Brandywine Global Investment Management LLC acquired a new stake in shares of Genmab A/S during the 4th quarter worth approximately $33,804,000. Two Sigma Advisers LP increased its holdings in shares of Genmab A/S by 168.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock worth $34,509,000 after buying an additional 1,038,400 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Genmab A/S by 122.2% during the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock worth $35,612,000 after buying an additional 938,455 shares during the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Genmab A/S by 162.2% during the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock worth $23,422,000 after buying an additional 694,243 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GMAB. HC Wainwright restated a "buy" rating and set a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Wall Street Zen upgraded shares of Genmab A/S from a "hold" rating to a "buy" rating in a report on Saturday, July 12th. Finally, Truist Financial lifted their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $37.80.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB traded down $0.13 during trading on Friday, hitting $21.88. The company's stock had a trading volume of 837,917 shares, compared to its average volume of 1,254,126. The business has a 50 day moving average price of $21.18 and a two-hundred day moving average price of $20.78. The company has a market capitalization of $14.04 billion, a PE ratio of 12.43, a P/E/G ratio of 6.69 and a beta of 0.94. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The business had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. As a group, equities analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.